BioNTech, known for its mRNA COVID-19 vaccine developed with Pfizer, announced the acquisition of German mRNA developer CureVac in an all-stock transaction valued at approximately $1.25 billion. The deal emphasizes acquiring CureVac's advanced research and manufacturing site in Tübingen, Germany. BioNTech aims to strengthen its cancer immunotherapy pipeline, leveraging CureVac’s platforms, as it gears towards new drug approvals later this year. CureVac has pivoted to oncology after divesting infectious disease vaccine rights and downsizing its workforce. The acquisition also resolves ongoing patent litigation between the two firms, removing legal uncertainties.